Emergent BioSolutions
NYSE/NASDAQ:EBSBiotechGaithersburg, Maryland, United States · Est. 2004 · 2,400 employees
Emergent BioSolutions is a speciality biopharmaceutical company focused on vaccines, specialty immunoglobulin products, and contract manufacturing services for the U.S. government and commercial customers.
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
1
Indications↗
Distinct diseases across all programs
43
Clinical Trials↗
All sponsored trials (all statuses)
5
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
Preclinical1
By Therapeutic Area
top 0
No TA breakdown available.
R&D Momentum
52/100
Pipeline Velocity
22/100
Trial Completion Rate
86/100
Pipeline Concentration
100/100
Pipeline Freshness
73/100
Activity
Key Events
Mar 3, 20268-KEmergent BioSolutions Inc. (EBS) (CIK 0001367644)
May 30, 2023TrialStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
Dec 21, 2021TrialStudy of SIAN Nasal Spray in Healthy Adults
Dec 7, 2021TrialA COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
Dec 1, 2021TrialUniversal Influenza A Vaccine in Healthy Adults
Jun 4, 2021FDATembexa — TEMBEXA
Jun 4, 2021FDATembexa — TEMBEXA
Dec 24, 2020TrialA COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
4 more events
Details
Company Info
Company Overview
$2.1B
Mkt Cap
$1.0B
Revenue
$111.7M
Cash
CEORobert G. Kramer
Founded2004
Employees2,400
HQGaithersburg, Maryland, United States
ExchangeNYSE/NASDAQ:EBS
Websiteemergentbiosolutions.com
LinkedInCompany Page
Therapeutic Focus
Infectious DiseaseOncologyOtherImmunologyNephrologyNeurologyRespiratory
Recent SEC Filings
8-KMar 3, 2026
Emergent BioSolutions Inc. (EBS) (CIK 0001367644)
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Unknown / Other
Unknown / Other
Complication
VIGIVPreclinical
Regulatory
Regulatory Timeline
20121 event
FDADec 14
RAXIBACUMAB — RAXIBACUMAB
Application BLA125349 (BLA)
20201 event
FDADec 21
EBANGA — EBANGA
Application BLA761172 (BLA)
20212 events
FDAJun 4
Tembexa — TEMBEXA
Application NDA214460 (NDA)
FDAJun 4
Tembexa — TEMBEXA
Application NDA214461 (NDA)
20261 event
SECMar 3
Emergent BioSolutions Inc. (EBS) (CIK 0001367644)
Accession: 001-33137
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)